Jefferies Sticks to Their Buy Rating for Cabaletta Bio (CABA)
Jefferies analyst Roger Song maintains a Buy rating for Cabaletta Bio with a $14.00 price target. The analyst consensus is a Strong Buy with an average price target of $17.83. Song, who covers the Healthcare sector, has an average return of -5.1% and a 37.50% success rate on recommended stocks.
In a report released today, Roger Song from Jefferies maintained a Buy rating on Cabaletta Bio, with a price target of $14.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Song covers the Healthcare sector, focusing on stocks such as United Therapeutics, Cabaletta Bio, and Oruka Therapeutics. According to TipRanks, Song has an average return of -5.1% and a 37.50% success rate on recommended stocks.
Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $17.83.
